Biotechnology company Aeolus Pharmaceuticals Inc (Other OTC:AOLS) reported on Wednesday the launch of an open-label, single centre, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of AEOL
10150 administered by subcutaneous injection in healthy subjects for national defense and oncology.
When added to the current standard therapy, AEOL
10150 improves survival to 100 percent.
Authority (BARDA) to develop AEOL
10150 Pulmonary Acute Radiation Syndrome.
The contract with BARDA will fully fund the development of AEOL
10150 as a treatment for radiation exposure resulting from a nuclear detonation, and puts the Company in a position to potentially file for Emergency Use Authorization as early as July 2013.
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) disclosed on Friday the exercise of USD3m in additional contract options for AEOL
10150 by Biomedical Advanced Research and Development Authority (BARDA) under the USD118m advanced research and development contract.
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL
10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) disclosed on Wednesday that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) seeking protection in all PCT contracting countries for its lead compound, AEOL
OTC: AOLS), a biopharmaceutical company developing a new class of broad spectrum catalytic antioxidant compounds that reduce oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS), has awarded Aeolus a contract for the advanced development of AEOL
10150 as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (ARS).
Biotechnology company Aeolus Pharmaceuticals Inc (OTCQB:AOLS) revealed on Thursday the receipt of notice for AEOL
10150 for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.
M2 PHARMA-January 24, 2014-Aeolus Pharmaceuticals Inc wins US FDA's Orphan Drug Designation for AEOL
10150 to treat patients exposed to acute radiation exposure
Aeolus is developing a broad-spectrum antioxidant drug known as AEOL
M2 EQUITYBITES-December 9, 2013-Aeolus Pharmaceuticals files provisional application for AEOL
10150 with US Patent and Trademark Office